At Schering-Plough, the Pain Only Grows

Schering-Plough's (SGP Quote) problems just got a whole lot tougher to cure.

The ailing drug manufacturer is now the target of a criminal investigation that one Wall Street analyst believes "may very well be broader, deeper and potentially more serious" than any probe that's hit the sector in recent history.

"This is a far more dangerous circumstance than any we've seen" since the '90s, says Fulcrum analyst Neil Sweig, who rates the stock a hold. "This is a great can of worms, if you will, that's been left to [new CEO] Fred Hassan." ...